Publications by authors named "Elisa Lucchini"

Claim this Profile
R
Real-world efficacy and safety of fostamatinib in ITP patients: Italian multicentre experience. GIMEMA ITP1122 study.
Elisa Lucchini, Nicola Vianelli, Ugo Consoli, Giuseppe Carli, Valentina Carrai

Br J Haematol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial.
Emanuele Zucca, Luca Ceriani, Giovannino Ciccone, Alice Di Rocco, Maria Cristina Pirosa, Elisa Lucchini

Blood· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of time to first progression and fitness status in elderly patients with mantle cell lymphoma: Results from the ELDERLY MANTLE-FIRST study.
Francesca Maria Quaglia, Annalisa Arcari, Lucia Morello, Luigi Marcheselli, Alessandra Tucci, Elisa Lucchini

Hemasphere· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study.
David J Kuter, Waleed Ghanima, Nichola Cooper, Howard A Liebman, Lei Zhang, Elisa Lucchini

Blood· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Large clones of clonal hematopoiesis affect outcome in mantle cell lymphoma: results from the FIL MCL0208 clinical trial.
Simone Ragaini, Anna Galli, Elisa Genuardi, Martina Gandossini, Beatrice Alessandria, Elisa Lucchini

Blood Adv· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results.
Maurizio Martelli, Luca Ceriani, Giovannino Ciccone, Umberto Ricardi, Iryna Kriachok, Elisa Lucchini

J Clin Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carfilzomib, lenalidomide, dexamethasone (KRD) in BTKi relapsed or refractory mantle cell lymphoma: A phase II study from Fondazione Italiana Linfomi.
Federica Cavallo, Michele Clerico, Elisa Lucchini, Anna Castiglione, Alessandro Re

Br J Haematol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study.
Marco Herling, Claire Dearden, Francesco Zaja, Dima El-Sharkawi, Wei Ding, Elisa Lucchini

Blood Adv· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Teclistamab salvage therapy for multiple myeloma relapse after allogeneic hemopoietic stem cell transplant: A case report.
Francesco Zaja, Elisa Lucchini, Monica Poiani, Eugenio Sbisà, Sara Mohamed

Am J Hematol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the Fondazione Italiana Linfomi MCL0208 trial.
Simone Ferrero, Daniele Grimaldi, Elena Arrigoni, Mariapia Pironti, Gian Maria Zaccaria, Elisa Lucchini

Blood Adv· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nationwide Survey on the Use of Thrombopoietin Receptor Agonists (TPO-RA) for the Management of Immune Thrombocytopenia in Current Clinical Practice in Italy.
Mariasanta Napolitano, Nicola Vianelli, Lisanna Ghiotto, Silvia Cantoni, Giuseppe Carli, Elisa Lucchini

Mediterr J Hematol Infect Dis· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serological and cellular response to mRNA-SARS-CoV2 vaccine in patients with hematological lymphoid malignancies: Results of the study "Cervax".
Sara Mohamed, Elisa Lucchini, Francesca Sirianni, Marika Porrazzo, Laura Ballotta

Front Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy.
Lisa Argnani, Alessandro Broccoli, Cinzia Pellegrini, Alberto Fabbri, Benedetta Puccini, Elisa Lucchini

Hemasphere· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Case report: Long-lasting SARS-CoV-2 infection with post-COVID-19 condition in two patients with chronic lymphocytic leukemia: The emerging therapeutic role of casirivimab/imdevimab.
Laura Ballotta, Omar Simonetti, Pierlanfranco D'Agaro, Ludovica Segat, Raffaella Koncan, Elisa Lucchini

Front Oncol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience" [Leukemia Res. 114 (March 2022) 106803].
Eleonora De Bellis, Silvia Imbergamo, Anna Candoni, Albana Liço, Ilaria Tanasi, Elisa Lucchini

Leuk Res· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience.
Eleonora De Bellis, Silvia Imbergamo, Anna Candoni, Albana Liço, Ilaria Tanasi, Elisa Lucchini

Leuk Res· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic and phenotypic attributes of splenic marginal zone lymphoma.
Ferdinando Bonfiglio, Alessio Bruscaggin, Francesca Guidetti, Lodovico Terzi di Bergamo, Martin Faderl, Elisa Lucchini

Blood· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab and Bendamustine (BR) Compared with Rituximab, Bendamustine, and Cytarabine (R-BAC) in Previously Untreated Elderly Patients with Mantle Cell Lymphoma.
Giulia Bega, Jacopo Olivieri, Marcello Riva, Greta Scapinello, Rossella Paolini, Elisa Lucchini

Cancers (Basel)· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax Shows Low Therapeutic Activity in BCL2-Positive Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase 2 Study of the Fondazione Italiana Linfomi.
Laura Ballotta, Pier Luigi Zinzani, Stefano Pileri, Riccardo Bruna, Monica Tani, Elisa Lucchini

Front Oncol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia.
Francesca Palandri, Elena Rossi, Daniela Bartoletti, Antonietta Ferretti, Marco Ruggeri, Elisa Lucchini

Blood· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune checkpoint inhibitors in combination with radiotherapy as salvage treatment for relapsed/refractory classical Hodgkin lymphoma: A retrospective analysis in 12 patients.
Elisa Lucchini, Chiara Rusconi, Mario Levis, Francesca Ricci, Armando Santoro

Hematol Rep· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eltrombopag second-line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off-treatment: results of a phase II, multicentre, prospective study.
Elisa Lucchini, Francesca Palandri, Stefano Volpetti, Nicola Vianelli, Giuseppe Auteri

Br J Haematol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Case Report: Cardiac Involvement by Lymphoma: Rare but Heterogeneous Condition With Challenging Behaviors.
Elisa Lucchini, Marco Merlo, Mario Ballerini, Aldostefano Porcari, Gianfranco Sinagra

Front Oncol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study.
Carlo Visco, Francesco Rodeghiero, Alessandra Romano, Federica Valeri, Michele Merli, Elisa Lucchini

Blood· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019?
Elisa Lucchini, Francesco Zaja, James Bussel

Haematologica· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis